Icon

LATUDA (nda200603)- (20MG,40MG,60MG,80MG,120MG)

LURASIDONE HYDROCHLORIDE SUNOVION PHARMS INC
20MG,40MG,60MG,80MG,120MG
Yes No
2031-Nov-23 2015-Oct-28
None None
None No
LATUDA is an atypical antipsychotic indicated for the treatment of:  Schizophrenia in adults and adolescents (13 to 17 years)  Depressive episode associated with Bipolar I Disorder (bipolar depression) in adults and pediatric patients (10 to 17 years) as monotherapy  Depressive episode associated with Bipolar I Disorder (bipolar depression) in adults as adjunctive therapy with lithium or valproate.
14 2 14
Total Other Developers 17
Drugs with Suitability No
20MG ** ** Down - 11
40MG ** ** Down - 11
60MG ** ** Down - 10
80MG ** ** Down - 12
120MG ** ** Down - 10
NDA Sales Available Total Generic Sales Available
Yes 12
ANDA No Generic Co Manufacturer Name Operations Manufacturer Address Country
****** ** ****** **. *****'* ************ ******* *********** ***-*** - ******* **** - **, ****** ** ******,**,**&**, ****** ** * ** ** & ** ** **, **************** ******* ***********(*),, **********, ****** ******* ******, ***** (***) ***
****** ****** ******** ***** *************** ******* *********** **** **. ***/***-****** / **** **.***/****-*********** , *******-***** ******* , ****** -******, ******, *********, ******* ******, ***** (***) ***
****** *** ***** *** ************** ********** ******* *********** ****** **. ****, *****, ***** ********* ** ***** *** ***** ****** *** ***** *** *** ******, ***** (***) ***
****** ******* ******* *************** ******* *********** *********** ********, ******* *******, *.*. *******, **** *****, ****** *****,, **********, ******* ******, ***** (***) ***
****** ******* ***** ******** *.*.*. *********** ****** ****** ********** **, ******, *****, ******* (***) ***
****** *** *** ************ ******* ******* *********** ************ ********, ****-**, ****** ***. ****& **** ** ****, ********* (*******), ********* (******), ********** ********, ********* ******, ***** (***) ***
****** *** *** *************** *** *********** **, **** ****, **********, *** ****** (**) *****, ****** ****** (***) ***
****** ********* ****** *** ********* ****** ******* *********** ****-***, ** **. ***/*, ***/*, ***/*, ***/* & ***/*, **** ** **** ***, *****, ***** ********** ****, *********, ********* ******, ************, ********* ******, ***** (***) ***
****** ********* ****** *** ******** ****** ******* ******* *** *********** ****-**, **.**'*.**,**,**,**,** ** **,***&***, ************** * & **.** *,*,****,**,**,**,**&**, ************ *, *********** ******, **********, ****** ******* ******, ***** (***) ***
****** ***** **** *** ***** ************ ******* *********** ****** ** ****, ****, ****, **** ******* *****, ****** ********, *****, ******** ******* ******, ***** (***) ***
****** ******* ****** ******* ***************, *** *********** * **** ***., *********, *** **** (**) *****, ****** ****** (***) ***
****** ***** ****** ***** ************ ******* *********** **** **. *-*/*&* *******, (******* ******** ****) ******, ******* ***** *.*. **. **, ***-******, ****-*********, *********, ******* ******, ***** (***) ***
****** ******** ****** *** ****** **** *********** ******* *****, *.*. **********, ****** - *****, *****, ******** ******* ******, ***** (***) ***
****** ******* ******* *************** ******* *********** *********-******* *******, ******, ******-****, ****. *******, ******, ******* ******, ***** (***) ***
****** ******* ******* *************** ******* *** *********** *********-******* *******, ******, ******-****, ****. *******, ******, ******* ******, ***** (***) ***
****** ******** ****** **** ******** ****** **** ***. */*/* **** *************** **** ***. *********** *** ******* **, **** *********, *** ****** (**) *****, ****** ****** (***) ***
****** ***** *** ****** ******* ****** ******* *** *********** **.***. *-**, **/* *** **/*, ****** *******, ***** ******, **********, ********* ******, ***** (***) ***
****** ***** *** ****** ******* ****** ******* *********** **** **. **-**, ****** **, ******** ****, *********, ****** ******* ******, ***** (***) ***
****** ****** ****** ****** ****** ******* ******* *********** ****** **. ***, ******* *******, *********** ******,, **********, ********* ******, ***** (***) ***
****** ** ****** **. *****'* ************ *********, *** *********** **** **** ******, **********, ********* (**) *****, ****** ****** (***) ***

Download GenUS Drug Report


Download GenUS Detailed Report


To get detailed report Contact Us

GenUs Advanced Search




Expired
to
Expired
to


Brand Name Generic Name Strength Dosage Route of Administration Innovator ParaIV

Please contact contact@researchdelta.com to get more details.